HFS
ABUS icon

Hughes Financial Services’s Arbutus Biopharma ABUS Stock Holding History

Hughes Financial Services’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$5 – 1841
2026
Q1 		$5 Buy
+1
New +$4 ﹤0.01% 1710

Other funds holding ABUS

LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return
WMA
Wealth Management Associates Cherry Hill, New Jersey $362M AUM 33.28% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PPWP
Premier Path Wealth Partners Madison, New Jersey $870M AUM 30% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
WFA
WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Hughes Financial Services's ABUS Position: Q2 2026 in Review

Hughes Financial Services sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 1 share — an estimated $5 sold.

Hughes Financial Services first reported a position in ABUS in Q1 2026 and held it in 1 quarter. The position peaked at $5 in Q1 2026. 11 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Hughes Financial Services reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Hughes Financial Services sold 1 Arbutus Biopharma share in Q2 2026, an estimated $5.
  • Hughes Financial Services first reported a position in Arbutus Biopharma in Q1 2026 and held it in 1 quarter.
  • Hughes Financial Services's Arbutus Biopharma position peaked at $5 in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.